Clinical Takeaways #
Cognition #
NAD⁺ IV therapy has shown a short-term cognitive performance boost in early trials, whereas NMN (as a NAD⁺ precursor) has not yet proven cognitive benefits in humans. Both mechanistically support neuronal health, but robust clinical evidence is lacking. NAD⁺ IV may offer transient cognitive enhancement, while NMN’s potential neuroprotective effects will require larger, longer studies to validate.
Metabolic Health #
NMN therapy has shown tangible metabolic benefits (e.g., improved insulin sensitivity) in clinical studies, whereas NAD⁺ IV is supported by strong theoretical rationale but remains unproven for metabolic outcomes in humans. NMN’s NAD⁺-boosting effect appears to enhance metabolic function over weeks.
Anti-Aging #
Replenishing NAD⁺ (by NMN precursors or NAD⁺ IV) is a plausible strategy to mitigate age-related decline, grounded in strong biology, but human clinical evidence is still preliminary. NMN has shown safety and hints of improved muscle performance in older adults, whereas NAD⁺ IV is promoted for longevity based on mechanistic insight without direct proof of slowing aging in humans.
Performance #
NMN has shown measurable improvements in endurance performance in clinical studies, whereas NAD⁺ IV is mainly backed by theory and anecdote for fatigue reduction. For now, NMN appears more substantiated for enhancing aerobic capacity.
Current State of Evidence #
Most human studies so far are small, short-term, and focus on safety or intermediate biomarkers rather than hard clinical endpoints. Encouragingly, both modalities appear safe and well-tolerated. No serious adverse effects have been attributed to raising NAD⁺ levels in clinical trials.
Ongoing Trials #
As of 2024, over 20 trials of NMN are registered, spanning indications from Alzheimer’s disease to heart failure to COVID-19. A proprietary NMN analog (MIB-626) is in Phase 2 trials. Within the next 1–2 years, more published data is expected on cognitive impairment, heart aging, and immunosenescence.
Clinical Recommendation #
Given the paucity of large clinical outcomes data, both therapies should be viewed as adjuncts — potentially useful in personalized protocols — but not as standalone cures. Each patient’s context (goals, tolerance, access) will guide whether NMN or NAD⁺ IV is the preferred modality.
